{"title": "Comirnaty [monovalent], Pfizer-BioNTech COVID-19 Vaccine [monovalent], or Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original/Omicron BA.4/BA.5)", "author": null, "url": "https://www.pfizermedicalinformation.com/en-us/pfizer-biontech-covid-19-vaccine", "hostname": "pfizermedicalinformation.com", "description": "COVID-19 mRNA vaccine (BNT162) medication page for healthcare professionals to search for scientific information on Pfizer medications. Also find the prescibing information, announcements, resources, and channels to connect with Pfizer Medical Information.", "sitename": "Comirnaty [monovalent], Pfizer-BioNTech COVID-19 Vaccine [monovalent], or Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original/Omicron BA.4/BA.5) | Pfizer Medical Information", "date": "2023-01-01", "cleaned_text": "If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents. Before administration of the vaccine, for important treatment considerations, please review the Emergency Use Authorization (EUA) Fact Sheet, which is available at [https://www.pfizer.com/products/product-detail/pfizer-biontech-covid-19-vaccine](https://www.pfizer.com/products/product-detail/pfizer-biontech-covid-19-vaccine) or at [www.pfizer.com/products](https://www.pfizer.com/products). Emergency uses of the vaccines have not been approved or licensed by the U.S. Food and Drug Administration (FDA), but have been authorized by the FDA, under an EUA for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Comirnaty [original monovalent] and Pfizer-BioNTech COVID-19 Vaccine [original monovalent] are no longer authorized for vaccination under the EUA. Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), hereafter referred to as Pfizer-BioNTech COVID-19 Vaccine, Bivalent, is authorized for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. Please review the [FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE: EMERGENCY USE AUTHORIZATION OF PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)](https://labeling.pfizer.com/ShowLabeling.aspx?id=19542)for more complete information, including the dosage and administration of the vaccine based on age, vaccination history, and immune status. Comirnaty [monovalent], Pfizer-BioNTech COVID-19 Vaccine [monovalent], or Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original/Omicron BA.4/BA.5) If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents. COVID-19 Vaccines (Pfizer/BioNTech) Quick Finder Resources *Contact Medical Information. Submit a medical question for Pfizer prescription products. To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: [Pfizer Safety Reporting Site](https://www.pfizersafetyreporting.com/) *If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site. If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at [(800) "}